March 2026
Consensus Article
SGLT2 Inhibitors in the Primary Health Care Setting: Consensus, Challenges, and Clinical Use
Ajay Chhabra, Vk Dhandania, Sunil Mishra, Girish Parmar, Suneet Verma, Meenakshi Verma, Dk Singh, Jk Rath, Mk Bhadani, Pc Runnu, Jaikant Prasad, Akanksha Sonkar, Sanjay Kalra
Diabetes & Endocrinology
Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a major advancement in the pharmacological management of type 2 diabetes mellitus (T2DM), with robust evidence demonstrating benefits beyond glycemic control. They offer additional health benefits such as lowering the risk of heart failure.... READ MORE
   Read More